Literature DB >> 6773019

Circulating immune complexes in cystic fibrosis.

M Berdischewsky, M Pollack, L S Young, D Chia, A B Osher, E V Barnett.   

Abstract

Recurrent respiratory infections associated with "mucoid" Pseudomonas aeruginosa characterize the advanced stages of cystic fibrosis. To determine if chronic antigenic stimulation is associated with circulating immune complexes (CIC), we assayed the sera of 20 hospitalized patients using the technique of precipitation with 4% polyethylene glycol. Elevated CIC levels, defined by > 310 micrograms IgG per ml, were found in 18 of 20 patients, (range, 350 to 3200 micrograms/ml). Serum, supernatant, and resuspended precipitates were assayed for hemagglutinating antibodies against pseudomonas lipopolysaccharide (LPS or endotoxin) and exotoxin A antigens. Both serum anti-LPS (range, 1:64 to 1:2048) and antitoxin titers (range, 1:64 to 1:16, 384) were markedly elevated and higher than titers in supernatants and resuspended precipitates, indicating antibody excess. "Enrichment" ratios for antibodies present in CIC were calculated by proportion of titer to immunoglobulin in the precipitated complex relative to these values in serum. Mean enrichment ratios of 13.1 and 13.9 were obtained for LPS antibody before and after 2 mercaptoethanol reduction, but the mean enrichment ratio for antitoxin was only 2.07. Serially diluted supernatants and precipitates were boiled for 1 hr and tested for endotoxin-like activity by the limulus test. At > 1:8 dilutions, precipitates were positive, and supernatants were negative. These findings indicate that CIC's are common in advanced cystic fibrosis, and analysis of the precipitated complexes demonstrates significant (> 13-fold) enrichment of antibodies against LPS but not exotoxin antigens, as well as endotoxin-like activity in boiled precipitates.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6773019     DOI: 10.1203/00006450-198006000-00011

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  11 in total

1.  The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion.

Authors:  D B Hornick; R B Fick
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

2.  Combined evaluation of circulating immune complexes and antibodies to Pseudomonas aeruginosa as an immunologic profile in relation to pulmonary function in cystic fibrosis.

Authors:  M K Dasgupta; P Zuberbuhler; A Abbi; F L Harley; N E Brown; K Lam; J B Dossetor; J W Costerton
Journal:  J Clin Immunol       Date:  1987-01       Impact factor: 8.317

3.  Detection of antibodies to Pseudomonas aeruginosa alginate extracellular polysaccharide in animals and cystic fibrosis patients by enzyme-linked immunosorbent assay.

Authors:  L E Bryan; A Kureishi; H R Rabin
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

4.  Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs.

Authors:  J E Pennington; W F Hickey; L L Blackwood; M A Arnaut
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

5.  Circulating soluble immune complexes containing pseudomonas antigens in cystic fibrosis.

Authors:  R W Pitcher-Wilmott; R J Levinsky; D J Matthew
Journal:  Arch Dis Child       Date:  1982-08       Impact factor: 3.791

6.  Immune complexes and Pseudomonas aeruginosa antibodies in cystic fibrosis.

Authors:  H P Van Bever; P L Gigase; L S De Clerck; C H Bridts; H Franckx; W J Stevens
Journal:  Arch Dis Child       Date:  1988-10       Impact factor: 3.791

7.  Isolation and characterization of circulating immune complexes in cystic fibrosis.

Authors:  R B Moss; Y P Hsu
Journal:  Clin Exp Immunol       Date:  1982-02       Impact factor: 4.330

8.  Protective immunization against chronic Pseudomonas aeruginosa pulmonary infection in rats.

Authors:  J D Klinger; H A Cash; R E Wood; J J Miler
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

9.  Functional immunoregulatory T-cell abnormalities in cystic fibrosis patients.

Authors:  N Lahat; J Rivlin; T C Iancu
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

10.  Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients.

Authors:  S Harkonen; P Scannon; R P Mischak; L E Spitler; C Foxall; D Kennedy; R Greenberg
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.